Roche’s Virtual Pipeline Event from WFH 2018 World Congress

Registration available from (CET timezone): 17.00, 23 May 2018

Agenda

Welcome

Karl Mahler, Head of Investor Relations

Hemophilia A without inhibitors remains an unmet medical need

Cristin Hubbard, Lifecycle Leader Hemlibra (emicizumab)

HAVEN 3: Phase 3 study of emicizumab prophylaxis in persons with hemophilia A without inhibitors

Johnny Mahlangu, MBBCh, MMed, Haemophilia Comprehensive Care Centre, Faculty of Health Sciences, University of the Witwatersrand and NHLS, Johannesburg, South Africa

HAVEN 4: Phase 3 study of emicizumab prophylaxis given every 4 weeks in persons with hemophilia A with and without inhibitors; additional comments

Gallia Levy, MD, Associate Group Medical Director Hematology

Q&A

Audio Webcast Replay

Please fill out the form to access the Audio webcast replay.

 

The registration form for the webcast is not available.

 

Please come back 30 minutes before the webcast start date and fill in the registration form.

* Mandatory